Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker.
Ohio-based LIB Therapeutics, LLC licensed development and commercialization rights to its Phase III cardiovascular candidate lerodalcibep (LIB003) in Greater China to Hasten Biopharmaceutic Co., Ltd. on 12 September
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?